ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » Connecticut » Pulmonary Disease

Top Pulmonary Disease Prescribers in Connecticut

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
PETER ROGOL MD

Pulmonary Disease

2,255

$366K

241
211 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

69%
prescriptions for brand name drugs

Avg: 64%

$162
Average prescription price

Avg: $170

JOHN RUSSOMANNO MD

Pulmonary Disease

2,254

$569K

317
273 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

80%
prescriptions for brand name drugs

Avg: 64%

$252
Average prescription price

Avg: $170

KEVIN TWOHIG MD

Pulmonary Disease

2,184

$424K

282
242 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

79%
prescriptions for brand name drugs

Avg: 64%

$194
Average prescription price

Avg: $170

ANDREW MURPHY M.D.

Pulmonary Disease

2,133

$221K

151
132 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

44%
prescriptions for brand name drugs

Avg: 64%

$103
Average prescription price

Avg: $170

JOSEPH HARRISON MD

Pulmonary Disease

2,089

$315K

269
230 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

72%
prescriptions for brand name drugs

Avg: 64%

$151
Average prescription price

Avg: $170

JAMES POPE M.D.

Pulmonary Disease

2,089

$493K

268
229 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

62%
prescriptions for brand name drugs

Avg: 64%

$236
Average prescription price

Avg: $170

ERIC SHORE MD

Pulmonary Disease

2,085

$687K

300
263 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

82%
prescriptions for brand name drugs

Avg: 64%

$330
Average prescription price

Avg: $170

SAIMA ANSARI M.D.

Pulmonary Disease

2,074

$478K

214
132 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

69%
prescriptions for brand name drugs

Avg: 64%

$230
Average prescription price

Avg: $170

LARRY WASSER M.D.

Pulmonary Disease

2,018

$301K

202
187 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

59%
prescriptions for brand name drugs

Avg: 64%

$149
Average prescription price

Avg: $170

FAUSTINUS ONYIRIMBA MD

Pulmonary Disease

1,992

$749K

267
202 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

78%
prescriptions for brand name drugs

Avg: 64%

$376
Average prescription price

Avg: $170

WILLIAM PRESKENIS MD

Pulmonary Disease

1,981

$287K

243
203 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

53%
prescriptions for brand name drugs

Avg: 64%

$145
Average prescription price

Avg: $170

PAUL GREIF M.D.

Pulmonary Disease

1,952

$416K

207
125 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

60%
prescriptions for brand name drugs

Avg: 64%

$213
Average prescription price

Avg: $170

MICHAEL CONWAY MD

Pulmonary Disease

1,937

$614K

332
303 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

68%
prescriptions for brand name drugs

Avg: 64%

$317
Average prescription price

Avg: $170

JASDEEP SIDANA M.D.

Pulmonary Disease

1,854

$402K

279
220 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

78%
prescriptions for brand name drugs

Avg: 64%

$217
Average prescription price

Avg: $170

SUMANGALA HUDED MD

Pulmonary Disease

1,782

$186K

116
107 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

38%
prescriptions for brand name drugs

Avg: 64%

$105
Average prescription price

Avg: $170

KEVIN WATSON MD

Pulmonary Disease

1,775

$326K

290
228 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

72%
prescriptions for brand name drugs

Avg: 64%

$184
Average prescription price

Avg: $170

PAUL LICATA D.O.

Pulmonary Disease

1,768

$335K

285
190 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

75%
prescriptions for brand name drugs

Avg: 64%

$190
Average prescription price

Avg: $170

RICHARD SMITH MD

Pulmonary Disease

1,760

$334K

207
165 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

78%
prescriptions for brand name drugs

Avg: 64%

$190
Average prescription price

Avg: $170

LESLIE LINDENBERG M.D.

Pulmonary Disease

1,723

$161K

96
69 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

14%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

33%
prescriptions for brand name drugs

Avg: 64%

$93
Average prescription price

Avg: $170

CURTLAND BROWN M.D.

Pulmonary Disease

1,703

$284K

204
178 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

74%
prescriptions for brand name drugs

Avg: 64%

$167
Average prescription price

Avg: $170

CAROLINE KURTZ MD

Pulmonary Disease

1,676

$217K

186
169 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

52%
prescriptions for brand name drugs

Avg: 64%

$130
Average prescription price

Avg: $170

ERIKA CAPPELLUTI MD

Pulmonary Disease

1,650

$333K

266
209 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

63%
prescriptions for brand name drugs

Avg: 64%

$202
Average prescription price

Avg: $170

MICHAEL TEIGER MD

Pulmonary Disease

1,611

$196K

176
133 are 65+

11%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

51%
prescriptions for brand name drugs

Avg: 64%

$122
Average prescription price

Avg: $170

STEVEN POWELL MD

Pulmonary Disease

1,576

$274K

224
178 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

60%
prescriptions for brand name drugs

Avg: 64%

$174
Average prescription price

Avg: $170

GANESH NATARAJAN M.D.

Pulmonary Disease

1,550

$333K

191
156 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

71%
prescriptions for brand name drugs

Avg: 64%

$215
Average prescription price

Avg: $170

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank